ConductScience.org, home

Paper78050

Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin.

Moncada S and 1 other. Lancet, 1978. Cited by 427 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Papers, record 78050. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/78050

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin.
PubMed
Journal
Lancet
PubMed
Year
1978
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
427
iCite
Relative citation ratio, by iCite
19.6
iCite
Revised in PubMed
2019-06-10
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Moncada SS
2Korbut RR

Source PubMed

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DipyridamoleMajor topic
EpoprostenolMajor topic
Fibrinolytic AgentsMajor topic
Phosphodiesterase InhibitorsMajor topic
Platelet AggregationMajor topic
ProstaglandinsMajor topic
ThrombosisMajor topic
Animals
Aspirin
Blood Platelets
Cyclooxygenase Inhibitors
Depression, Chemical
Dose-Response Relationship, Drug
Drug Synergism
Prostaglandin Antagonists
Prostaglandins, Synthetic
Rabbits
Theophylline

Source PubMed

Cited by45

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 427 citations.

PMIDTitleJournalYearIn PapersSource
33,001,004Potential Therapeutic Benefits of Dipyridamole in COVID-19 Patients.Curr Pharm Des2021https://conductscience.org/library/papers/33001004PubMed
23,024,160Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence?Clin J Am Soc Nephrol2013https://conductscience.org/library/papers/23024160PubMed
16,103,157Dipyridamole reversibly inhibits mengovirus RNA replication.J Virol2005https://conductscience.org/library/papers/16103157PubMed
15,733,010Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke.Drugs2005https://conductscience.org/library/papers/15733010PubMed
12,885,264Clinical pharmacokinetics of antiplatelet agents used in the secondary prevention of stroke.Clin Pharmacokinet2003https://conductscience.org/library/papers/12885264PubMed
10,768,906Intracoronary dipyridamole reduces the incidence of abrupt vessel closure following PTCA: a prospective randomised trial.Heart2000https://conductscience.org/library/papers/10768906PubMed
9,849,048[Effect of intracoronary dipyridamole administration on the incidence of restenosis after PTCA. A prospective randomized study].Med Klin (Munich)1998https://conductscience.org/library/papers/9849048PubMed
9,578,178Do we still need dipyridamole?Br J Clin Pharmacol1998https://conductscience.org/library/papers/9578178PubMed
8,970,869Short-term effect of dipyridamole on blood flow velocities in the extraocular vessels.Int Ophthalmol1995https://conductscience.org/library/papers/8970869PubMed
7,957,770Effect of dipyridamole on glomerular mesangial cell ecto-5'-nucleotidase expression.Experientia1994https://conductscience.org/library/papers/7957770PubMed
7,641,602Novel antithrombotic drugs in development.Drugs1995https://conductscience.org/library/papers/7641602PubMed
7,400,307Effects of aspirin and dipyridamole on the degradation of adenosine diphosphate by cultured cells derived from bovine pulmonary artery.J Clin Invest1980https://conductscience.org/library/papers/7400307PubMed
7,269,560Thrombosis: its role and prevention in cardiovascular events--Part I. Concepts of thrombogenesis and its prevention.West J Med1981https://conductscience.org/library/papers/7269560PubMed
7,262,095The haemolytic uraemic syndrome in childhood: a study of the long-term prognosis.Eur J Pediatr1981https://conductscience.org/library/papers/7262095PubMed
7,151,846Dipyridamole treatment in chronic obstructive airways disease: effect on platelet regeneration time.Eur J Clin Pharmacol1982https://conductscience.org/library/papers/7151846PubMed
7,077,562Transient cerebral ischaemic attacks.J R Coll Physicians Lond1982https://conductscience.org/library/papers/7077562PubMed
7,059,243Antiplatelet therapy reduces aortic intimal hyperplasia distal to small diameter vascular prostheses (PTFE) in nonhuman primates.Ann Surg1982https://conductscience.org/library/papers/7059243PubMed
7,049,287Effect of dipyridamole on the formation of 6-oxo-prostaglandin F1 alpha by the rat isolated aorta and ram seminal vesicle microsomes.Br J Pharmacol1982https://conductscience.org/library/papers/7049287PubMed
7,044,460Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin.Br J Pharmacol1982https://conductscience.org/library/papers/7044460PubMed
7,037,426Enhanced prostacyclin production by dipyridamole in man.Eur J Clin Pharmacol1981https://conductscience.org/library/papers/7037426PubMed

See all 45 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/78050

GET https://conductscience.org/api/papers/v1/78050/cited_by?page=2